Chronic pain

Avesta Partners with Veterans Affairs (VA) to Offer Free Ketamine Therapy to Eligible Veterans

Retrieved on: 
Wednesday, February 21, 2024
Anxiety, Esketamine, TRD, Ketamine, Suicide, History, Chronic pain, Depression, Patient, Teaching, PTSD, Veteran, Senior counsel, Veterans' affairs, Partnership

WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Avesta Ketamine and Wellness ("Avesta"), a leading provider of innovative mental health treatments, announced a partnership with Veterans Affairs (VA) to offer free ketamine therapy to eligible veterans. This initiative, available now in Avesta ketamine clinics across Washington, DC, Northern Virginia, and Bethesda, Maryland, will help veterans overcome treatment-resistant depression (TRD), PTSD, anxiety, chronic pain, and substance misuse disorders.

Key Points: 
  • WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Avesta Ketamine and Wellness ("Avesta"), a leading provider of innovative mental health treatments, announced a partnership with Veterans Affairs (VA) to offer free ketamine therapy to eligible veterans.
  • Avesta seeks to address these challenges by offering IV ketamine infusions and/or Spravato treatments to veterans who have not found relief through traditional therapies.
  • Avesta already partners with the Veterans Mental Health Coalition, a coalition committed to ending veterans' suicide, and views this new partnership as continuing its mission.
  • Thanks to Avesta's Veterans Care Agreement, veterans near McLean, Virginia, Bethesda, Maryland, and Washington D.C. are eligible to receive treatments at Avesta without financial burden.

Mindpath Health releases Daddy Issues: Understanding Attachment Trauma

Retrieved on: 
Wednesday, February 21, 2024
DSM, Incidence, Anxiety, Woman, Caregiver, Mental health, Emotion, Love Is Blind, Emotional dysregulation, Friends, Impulsivity, Love, Parent, Life, Risk, Perception, Dysphoria, Fear, Anhedonia, Family, Chronic pain, Hypervigilance, Child, ADHD, Trauma, DSM-IV codes, Doctor of Psychology, Personality disorder, Depression, Nursing

A psychological name for daddy issues: attachment trauma

Key Points: 
  • A psychological name for daddy issues: attachment trauma
    Clearly, 'daddy issues' is not a clinical term, and you won't find it in the DSM.
  • At its core, 'daddy issues' is a label for something very clinical: attachment trauma.
  • Like many forms of trauma, attachment trauma can have real effects on your mental health .
  • Attachment trauma, or the effects of inconsistent or abusive parenting, shows up in several different insecure attachment styles developed by psychologist John Bowlby .

Public advisory - APO-Mometasone nasal spray: Two lots recalled due to possible risk of infection

Retrieved on: 
Monday, February 19, 2024
Pharmacy, Sepsis, Health Canada, Infection, Polyp (medicine), Sneeze, Sinusitis, BCC, Chronic pain, Burkholderia cepacia complex, Fever, Risk, Bacteria, Death, Child, Inc., Pressure, Immune system

Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).

Key Points: 
  • Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).
  • APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old.
  • It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults.
  • The effects of Bcc vary widely, ranging from no symptoms at all to serious infections.

Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Woman, Committee, Acne, Monograph, Headache, Chronic pain, Breast, Hypothalamus, Dizziness, Nausea, Date, Mouth, Urinary system, Safety, Stomach, Premenstrual syndrome, Pituitary gland, Allergy, Rash, Patient, Fruit, Medicine, DSM-IV codes, Herbal medicine, Irritability, Ethanol, Brain, Dietary supplement

Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

BioElectronics Chairman Updates Investors

Retrieved on: 
Thursday, February 15, 2024
University, Motion, Doctor of Philosophy, OTC, Quality of life, Pain, Dog, Sale, Arthritis, Veterinary medicine, Thumb, Society, Chronic pain, Patient, Knee, Clinical trial, Osteoarthritis, Hand, Stanford University Medical Center, Literature, Twilight anesthesia, UCSD, Research, Audit

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Key Points: 
  • FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.
  • The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.
  • Today, I will focus on the first of these, although I will briefly mention the two other vital components of our mission.
  • Such findings will be new to the literature and should provide important evidence on reducing opioid use and minimizing post-surgical chronic pain.

First Clinical Study Validates the Impact of Personalized Music on Youth with Chronic Pain by The Songs of Love Foundation

Retrieved on: 
Thursday, February 15, 2024
Simmons University, Empowerment, Adolescent medicine, Chronic pain, Pain management, Nociception, Music, Song, Songs of Love, Research

The Songs of Love Foundation, a national nonprofit 501(c)(3) organization, has been dedicated to creating free, personalized, original songs for children and teens facing tough medical, physical, or emotional challenges for over 28 years.

Key Points: 
  • The Songs of Love Foundation, a national nonprofit 501(c)(3) organization, has been dedicated to creating free, personalized, original songs for children and teens facing tough medical, physical, or emotional challenges for over 28 years.
  • The study, titled "The acceptability of Songs of Love for youth living with chronic pain," marks a pivotal moment for The Songs of Love Foundation, demonstrating the effectiveness of personalized music as a complementary intervention for pain management.
  • It involved interviews with 15 youth who received a personalized song and six singer-songwriters who created the songs, exploring the program's acceptability from both perspectives.
  • The positive feedback from both the youth participants and the singer-songwriters involved in the study highlights the transformative power of personalized music."

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Retrieved on: 
Thursday, February 15, 2024
Fast Track, Recurrence, Scar, Inflammation, FDA, Quality of life, TSX, C-reactive protein, Myocarditis, Pericardial fluid, Pericarditis, Viral, CRDL, ODD, Safety, Pericardium, Therapy, Chronic pain, Fatigue, Length of stay, Patient, News, Disease, Heart, Hospital, Research, NRS, Priority review, Pharmaceutical industry

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis.
  • MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis.
  • The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention.

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Retrieved on: 
Wednesday, February 14, 2024
IDDS, Therapy, Fibromyalgia, Blood, Ketamine, Administration, Chronic pain, HCL, SILO, Medical device

SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.

Key Points: 
  • A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
  • In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings, 20% and 40%.
  • “Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo.
  • Silo believes that implantable drug delivery systems (IDDS) can offer a superior delivery alternative for sustained relief from chronic pain.

Texas Original Opens New San Antonio Location, Launches Dark Chocolate Bites

Retrieved on: 
Wednesday, February 14, 2024
Alternative Medicine, Retail, Health, Cannabis, Vitamins, Supplements, Online Retail, Pharmaceutical, Oncology, Mental Health, Other Retail, Physical Therapy, General Health, Natural Resources, Food, Beverage, Dark, Originality, Physician, Flavonoid, Diabetic neuropathy, Cannabinoid, Spasticity, Terpene, Chronic pain, Blue Dream, Patient, THC, Protein, Epilepsy, PTSD, RSO, Cancer, Drug

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest permanent prescription pickup location in San Antonio.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest permanent prescription pickup location in San Antonio.
  • Texas Original also announced the launch of its new Dark Chocolate Bites, the company’s first chocolate product and the state’s first medical cannabis chocolate product made with Rick Simpson Oil (RSO).
  • Like all Texas Original products, Dark Chocolate Bites are regulated and rigorously tested to ensure quality, consistency and purity.
  • The northeast San Antonio location is Texas Original’s third medical cannabis pickup location in the San Antonio area, joining the company’s existing locations in west San Antonio and Universal City.

NAVEGA THERAPEUTICS APPOINTS CAROL GREVE-PHILIPS CHIEF BUSINESS OFFICER

Retrieved on: 
Tuesday, February 13, 2024
Erythromelalgia, SAN, Spark Therapeutics, Therapy, Genzyme, Chronic pain, SCN9A, CIRM, Peripheral neuropathy, NIH, Pharmaceutical industry

SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Navega Therapeutics, a privately-held early-stage pharmaceutical company developing epigenetic gene therapies, today announced the appointment of Carol Greve-Philips as Chief Business Officer.

Key Points: 
  • SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Navega Therapeutics, a privately-held early-stage pharmaceutical company developing epigenetic gene therapies, today announced the appointment of Carol Greve-Philips as Chief Business Officer.
  • Ms. Greve-Philips brings 35 years of business development expertise to Navega as the company pursues development and commercialization agreements for its lead program, NT-Z001—an epigenetic gene therapy modulating SCN9A (Nav1.7).
  • She has led negotiations for collaborations, partnerships, mergers and acquisitions for biotech companies specializing in rare disease and gene therapy.
  • "Navega is thrilled to welcome Carol to our leadership team," said CEO Dr. Ana Moreno .